News

Public · Published

Wells Fargo maintains AbbVie at Overweight, raises price target to $340 from $300

Wells Fargo kept its Overweight rating on AbbVie and raised its price target to $340 from $300. The target is 13.3% higher than before and implies 15.3% upside from AbbVie's October 30 closing price of $294.89.

Published:

Updated:

What happened

Wells Fargo kept its Overweight rating on AbbVie and raised its price target to $340 from $300. The target is 13.3% higher than before and implies 15.3% upside from AbbVie’s October 30 closing price of $294.89.

Confirmed

Global impact / market context

The higher target signals Wells Fargo expects AbbVie shares to be worth more than its previous estimate. If investors act on that view, buying could support the share price; however, a target is an analyst estimate, not a guaranteed outcome or company forecast.

Analyst inference

Recent analyst targets listed in the article range from $294 to $338, while Wells Fargo’s new $340 target sits slightly above that range. This shows differing views on AbbVie’s value, rather than a settled market consensus.

Confirmed

What to watch

  1. Compare future analyst targets with Wells Fargo’s $340 estimate and the listed $294–$338 range to see whether views on AbbVie’s value converge or diverge. Analyst inference
  2. Watch for changes to Wells Fargo’s rating or target; the article reports the target increase but gives no explanation for the revised estimate. Confirmed
  3. Track AbbVie’s share price against the stated $294.89 October 30 close; the article’s 15.3% implied upside depends on that reference price. Confirmed

Evidence

  • Original source link unavailable